Advanced nanotechnology for integrated diagnosis and treatment

The multimodal diagnosis and treatment integration platform based on nanozyme is at the forefront of biomedical research. By leveraging the stimulus-responsive mechanism and efficient enzyme-like catalytic activity, nanozymes can ingeniously combine diagnosis and treatment, enabling real-time monitoring and precise treatment of diseases. In recent years, the application of Fe3O4 and upconversion nano-composite materials has significantly enhanced the sensitivity of imaging. At the same time, new nanozyme materials have further enhanced the therapeutic efficacy, supporting multimodal collaborative treatment and effectively reducing side effects. Although a series of progress has been made, this field still faces many challenges, including poor biocompatibility, limited catalytic efficiency of nanozymes, and difficulties in clinical translation. Developing new nanozymes, optimizing material design, delving into catalytic mechanisms, and strengthening interdisciplinary cooperation will be key to promoting paradigm shifts in treatment in areas such as cancer and cardiovascular and cerebrovascular diseases, and will advance the development of personalized medicine.

This research project aims to address the three core challenges faced by integrated diagnostic and therapeutic nanomaterials in clinical integration: insufficient biological safety, low catalytic efficiency of nanoenzymes, and obstacles in clinical translation. To solve these problems, current strategies include surface modification of materials, such as using biomimetic modification techniques like cell membrane coating to enhance biocompatibility; constructing multi-site synergistic nanoenzymes to increase catalytic activity; designing multi-modal stimulus-responsive intelligent systems that respond to the tumor microenvironment, and using microfluidic synthesis methods to improve targeting ability and drug release control performance. In recent years, AI-guided nanoenzyme carriers have not only achieved high drug loading, but also improved nanoenzyme activity, enhancing therapeutic efficiency. The development of degradable quantum dots has alleviated the risk of heavy metal toxicity, and the emergence of organ-on-a-chip technology has provided a more efficient evaluation platform for preclinical research. However, to achieve a true breakthrough, it is still necessary to systematically improve toxicology research and promote interdisciplinary collaboration to overcome the key bottleneck of low clinical translation efficiency.

In order to further deepen the interdisciplinary research on intelligent diagnostic and therapeutic nanomaterials, with a focus on the design of new nanoenzymes, diagnostic and therapeutic mechanisms, and clinical translation studies, we welcome papers discussing the following topics (but not limited to):
o Bionic nanoenzymes
o Multimodal diagnostic and therapeutic systems
o AI-driven nanoenzyme design and optimization
o Microfluidic preparation processes and microfluidic detection techniques
o Research on immunotherapy and cell signaling pathways
Priority is given to original research, including preclinical data, in-depth reviews of recent progress, and methodological innovations in characterization and preparation techniques.